A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Public ClinicalTrials.gov record NCT05652686. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label, Multicenter, Dose Escalation, and Dose Expansion Phase 1/2 Study With Peluntamig (PT217) Followed by a Key ChemotherapY and/or Checkpoint Inhibitor ComBination in Patients With NeuRoendocrIne Carcinomas That Are Known to be DLL3 expressinG CancErs (SKYBRIDGE)
Study identification
- NCT ID
- NCT05652686
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Phanes Therapeutics
- Industry
- Enrollment
- 203 participants
Conditions and interventions
Conditions
Interventions
- Atezolizumab Drug
- Carboplatin + Etoposide Drug
- Paclitaxel. Drug
- Peluntamig (PT217) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 4, 2023
- Primary completion
- Nov 30, 2027
- Completion
- Jul 31, 2028
- Last update posted
- Sep 22, 2025
2023 – 2028
United States locations
- U.S. sites
- 12
- U.S. states
- 10
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope (City of Hope National Medical Center, City of Hope Medical Center) | Duarte | California | 91010 | Recruiting |
| Sarah Cannon Research Institute at HealthONE | Denver | Colorado | 80218 | Recruiting |
| Sidney Kimmel Comprehensive Cancer Center at John Hopkins | Baltimore | Maryland | 21287 | Recruiting |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | Recruiting |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | Recruiting |
| Washington University School of Medicine (Siteman Cancer Center) | St Louis | Missouri | 63108 | Recruiting |
| University of North Carolina at Chapel Hill | Chapel Hill | North Carolina | 27599 | Recruiting |
| Sarah Cannon Research Institute University of Oklahoma | Oklahoma City | Oklahoma | 73104 | Recruiting |
| Providence Portland Medical Center | Portland | Oregon | 97213 | Recruiting |
| The University of Texas, MD Anderson Cancer Center | Houston | Texas | 77030 | Not yet recruiting |
| Mays Cancer Center / University of Texas, San Antonio | San Antonio | Texas | 78229 | Recruiting |
| NEXT Virginia | Fairfax | Virginia | 22031 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05652686, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 22, 2025 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05652686 live on ClinicalTrials.gov.